BluePath SolutionsBluePath Solutions
Search
  • Home
  • About
  • Solutions
    • Our approach
    • Value Marketing & Communications
    • Modeling & Data Visualization
    • Health Economics & Outcomes Research
  • The Compass
  • Careers
  • Contact us
  • Home
  • Systematic Review of Signs and Symptoms Associated with HSCT-TMA
  • Featured

Featured

26JanJanuary 26, 2023

Systematic Review of Signs and Symptoms Associated with HSCT-TMA

Otis2023-01-26T18:11:31+00:00

Our colleagues recently participated in the first systematic literature review and meta-analysis on the signs and symptoms associated with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The recent open access...

By OtisBlog, Featured0 Comments
Read more...
18NovNovember 18, 2022

A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy

Otis2022-11-18T20:16:57+00:00

With the marketplace flush with Chimeric antigen receptor (CAR) T-cell therapies to treat relapsed/refractory large B-cell lymphoma (LBCL), one of the key clinical and economic differentiators may be the risk...

By OtisBlog, Featured0 Comments
Read more...
18NovNovember 18, 2022

Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients

Otis2022-11-18T20:16:52+00:00

A recent publication by our colleagues uses real world data to demonstrate the real world effectiveness of a recently approved therapy while maintaining safe outcomes. Extended-release calcifediol (ERC), active vitamin...

By OtisBlog, Featured0 Comments
Read more...
18NovNovember 18, 2022

Breast, Colorectal, Lung, Prostate, and Cervical Cancer Screening Prevalence in a Large Commercial and Medicare Advantage Plan, 2008–2020

Otis2022-11-18T20:16:46+00:00

Our colleagues recently published a large-scale analysis to comprehensively assess breast, colorectal, cervical, lung, and prostate cancer screening rates and trends in the US over time among individuals for whom...

By OtisBlog, Featured0 Comments
Read more...
14OctOctober 14, 2021

Medicare Part D Direct & Indirect Remuneration

Otis2021-10-15T08:52:09+00:00

Payers who offer Medicare Part D plans may receive additional compensation after the point-of-sale. These funds are known as Direct & Indirect Remuneration (DIR), and account for growing levels of...

By OtisBlog, Featured0 Comments
Read more...
27FebFebruary 27, 2019

Overview of Proposed Rule Changes to “Safe Harbor” Regulation

Otis2021-10-15T11:27:55+00:00

Health and Human Services (HHS) is proposing to eliminate safe harbor protection for manufacturer reductions in price on prescription pharmaceutical products to Medicare Part D plans, PBM’s, and Medicaid Managed...

By OtisBlog, Featured0 Comments
Read more...
27MayMay 27, 2018

CAR-T Commercial Market Access Brief – A Review of Initial Brand Access at Select US Payers

Otis2021-10-15T11:28:35+00:00

Chimeric Antigen Receptor T-cell (CAR-T) therapies represent a breakthrough in cancer care due to the significant clinical response induced in patients who do not respond to currently available treatments. In...

By OtisBlog, Featured0 Comments
Read more...
15MayMay 15, 2018

A Snapshot of the Conclusions on Long-term Value of Healthcare Treatments Conducted by the Institute for Clinical and Economic Review Group

Otis2021-10-15T11:29:34+00:00

The Institute for Clinical and Economic Review, a non-profit institute evaluates the cost-effectiveness of drugs, medical devices, medical procedures, and diagnostics. The Institute for Clinical and Economic Review has published...

By OtisBlog, Featured0 Comments
Read more...
01NovNovember 1, 2017

US Market Access – Key Considerations in a Changing Environment

Otis2021-10-15T11:30:13+00:00

Many life science manufacturers employ a payer size and control strategy in the US market. While this continues to be viable model, changes in formulary and benefit design result in...

By OtisBlog, Featured0 Comments
Read more...
02OctOctober 2, 2017

Emerging Barriers to Launch Access – the Impact of New Drug Coverage Policies

Otis2021-10-14T05:37:09+00:00

New drug coverage policies provide guidance around a payer’s coverage of new drugs in the time period between FDA approval and P&T committee review. As these policies proliferate, manufacturers may...

By OtisBlog, Featured0 Comments
Read more...

Recent Posts

26JanJanuary 26, 2023

Systematic Review of Signs and Symptoms Associated with HSCT-TMA

Our colleagues recently participated in the first systematic literature review and meta-analysis on the signs... read more

18NovNovember 18, 2022

A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy

With the marketplace flush with Chimeric antigen receptor (CAR) T-cell therapies to treat relapsed/refractory large... read more

18NovNovember 18, 2022

Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients

A recent publication by our colleagues uses real world data to demonstrate the real world... read more

18NovNovember 18, 2022

Breast, Colorectal, Lung, Prostate, and Cervical Cancer Screening Prevalence in a Large Commercial and Medicare Advantage Plan, 2008–2020

Our colleagues recently published a large-scale analysis to comprehensively assess breast, colorectal, cervical, lung, and... read more

14OctOctober 14, 2021

Medicare Part D Direct & Indirect Remuneration

Payers who offer Medicare Part D plans may receive additional compensation after the point-of-sale. These... read more

  • Home
  • About
  • Solutions
  • The Compass
  • Careers

Contact us

1640 S Sepulveda Blvd, Suite 207
Los Angeles, CA 90025
United States

855.378.4115
310.774.0406

Follow BPS

Linkedin
veeva logo
hippa logo

©2021 BluePath Solutions, All Rights Reserved

  • Privacy Policy
  • Terms
BluePath Solutions © Copyright 2021. All Rights Reserved.
  • Home
  • About
  • Solutions
    • Our approach
    • Value Marketing & Communications
    • Modeling & Data Visualization
    • Health Economics & Outcomes Research
  • The Compass
  • Careers
  • Contact us